Core Viewpoint - The stock of Baixinan-B (02185) has seen a significant increase, with a rise of over 14% during trading, currently reported at 8.70 HKD, with a trading volume of 109 million HKD. This surge is attributed to positive developments in the renal denervation (RDN) market, particularly following Boston Scientific's acquisition of SoniVie for 600 million USD and updates to hypertension treatment guidelines by major American health organizations [1]. Company Summary - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage in the market [1]. - The company has established strategic partnerships with Yuan Da Health and other international entities, which are expected to accelerate its commercialization efforts [1]. Industry Summary - The RDN procedure is emerging as a new therapeutic approach for uncontrolled and resistant hypertension, with a projected market size in China exceeding 10 billion RMB by 2032, according to Frost & Sullivan [1]. - Recent updates from the American College of Cardiology and the American Heart Association have included RDN in their IIb level recommendations for hypertension treatment, indicating a growing acceptance and potential for clinical application [1]. - The proposed national coverage decision by the Centers for Medicare & Medicaid Services (CMS) in the U.S. is expected to significantly expedite the clinical promotion and application of RDN if approved [1].

Core Viewpoint - Baixinan-B (02185) has seen a significant stock price increase of over 10%, currently up 13.5% at HKD 8.83, with a trading volume of HKD 106 million [1] Group 1: Market Developments - Boston Scientific is set to acquire SoniVie for a total price of USD 600 million, actively entering the RDN (Renal Denervation) market by March 2025 [1] - The American College of Cardiology and the American Heart Association updated hypertension treatment guidelines in August, incorporating RDN as a Class IIb recommendation [1] - The Centers for Medicare & Medicaid Services (CMS) proposed a national coverage decision for RDN in July, which, if approved, will significantly accelerate clinical adoption [1] Group 2: Industry Insights - RDN is a new therapeutic device for uncontrolled and resistant hypertension, with the Chinese RDN market expected to exceed RMB 10 billion by 2032 according to Zhi Shi Consulting [1] - Baixinan's Iberis RDN system is the only globally approved device that offers both transradial (TRA) and transfemoral access for RDN, providing a significant first-mover advantage [1] - Strategic partnerships have been established with Yuan Da Health and other international companies to accelerate commercialization, with Germany and France already including Iberis RDN in their healthcare coverage [1]